(VIANEWS) – GETLINK SE (GET.PA), SANOFI (SAN.PA), SPAREBANK 1 SMN (MING.OL) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up to now. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. GETLINK SE (GET.PA)
75.76% Payout Ratio
Getlink SE engages in the design, finance, construction, and operation of fixed link infrastructure and transport system in France. The company operates through Eurotunnel, Europorte, and ElecLink segments. The Eurotunnel segment operates three tunnels of a length of approximately 50 kilometres each under the English Channel, as well as two terminals at Folkestone in the United Kingdom and the Coquelles in France. It also provides passenger shuttle services for the transport of trucks, cars, motor homes, coaches, and other vehicles. In addition, this segment manages high-speed passenger trains and rail freights, as well as fixed equipment and related installations. The Europorte segment offers a range of integrated rail freight services, including national and international haulage, local services for secondary lines, individual junction management, infrastructure maintenance, and wagon loading and unloading services. The ElecLink segment engages in the construction and operation of a 1 gigawatt electricity interconnector between the France and Great Britain. Getlink SE also engages in third-party retail, telecommunication cables, training activity, and property businesses, as well as the sale of travel insurance products. The company was formerly known as Groupe Eurotunnel S.E. and changed its name to Getlink SE in April 2018. Getlink SE was founded in 1986 and is based in Paris, France.
Earnings Per Share
As for profitability, GETLINK SE has a trailing twelve months EPS of €0.66.
PE Ratio
GETLINK SE has a trailing twelve months price to earnings ratio of 25.63. Meaning, the purchaser of the share is investing €25.63 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.74%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 3.37%.
More news about GETLINK SE.
2. SANOFI (SAN.PA)
49.31% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €7.22.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 11.84. Meaning, the purchaser of the share is investing €11.84 for every euro of annual earnings.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 2.9% and a drop 10.6% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.3%, now sitting on 45.7B for the twelve trailing months.
More news about SANOFI.
3. SPAREBANK 1 SMN (MING.OL)
47.74% Payout Ratio
SpareBank 1 SMN, together with its subsidiaries, provides various banking, accounting, and real estate products and services to private individuals and companies in Norway and internationally. The company offers mortgage, car, boat, other vehicles, and consumer loans; refinancing; and current, savings, billing, business, group, tax deduction, currency, and deposit accounts. It also provides BSU house savings for young people; fixed interest deposits; stocks and investments; cash services; and payments. In addition, the company offers vehicle, housing and travel, person, animal, and valuables insurance services; property buying and selling advisory services; and mobile and online banking, and various cards. Further, it offers loans and financing, including bank guarantees, business and construction loans, operating credit for agriculture, factoring, guarantees, leasing, and overdrafts; various pension products; and business and personal insurance products. Additionally, the company provides document collection, letter of credit, future business, and currency option services; and services, including accounting and payroll, HR, taxes and duties, and transfer of ownership, as well as IT solutions. It offers real estate agency, advisory, and external and equity financing services. SpareBank 1 SMN was founded in 1823 and is headquartered in Trondheim, Norway.
Earnings Per Share
As for profitability, SPAREBANK 1 SMN has a trailing twelve months EPS of kr13.62.
PE Ratio
SPAREBANK 1 SMN has a trailing twelve months price to earnings ratio of 9.49. Meaning, the purchaser of the share is investing kr9.49 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.51%.
Moving Average
SPAREBANK 1 SMN’s value is below its 50-day moving average of kr136.44 and below its 200-day moving average of kr135.42.
More news about SPAREBANK 1 SMN.
4. TUBIZE-FIN (TUB.BR)
43.03% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €2.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 33.4. Meaning, the purchaser of the share is investing €33.4 for every euro of annual earnings.
Moving Average
TUBIZE-FIN’s worth is higher than its 50-day moving average of €66.47 and below its 200-day moving average of €71.90.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 1.29%.
Volume
Today’s last reported volume for TUBIZE-FIN is 3447 which is 59.11% below its average volume of 8430.
More news about TUBIZE-FIN.
5. CRH PLC ord (CRG.IR)
32.99% Payout Ratio
CRH plc, through its subsidiaries, manufactures and distributes building materials in Ireland and internationally. It operates through three segments: Americas Materials, Europe Materials, and Building Products. The company manufactures and supplies cement, lime, aggregates, precast, ready mixed concrete, and asphalt products; concrete masonry and hardscape products comprising pavers, kerbs, retaining walls, and related patio products; It also offers precast concrete and polymer-based products, such as underground vaults, drainage pipes and structures, utility enclosures, and modular precast structures to the water, energy, communication, transportation, and building structures markets; and construction accessories, such as engineered anchoring, fixing, and connection solutions, as well as lifting systems, formwork accessories, and other accessories used in construction applications. In addition, the company offers network access products, which include composite access chambers, covers, passive safety systems, retention sockets, sealants, and meter boxes; and paving and construction services. Further, it provides building and civil engineering contracting, contract surfacing, operates logistics and owned railway infrastructure; sells and distributes cement; and supplies access chambers and ducting products. CRH plc was founded in 1936 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, CRH PLC ord has a trailing twelve months EPS of €3.6.
PE Ratio
CRH PLC ord has a trailing twelve months price to earnings ratio of 13.98. Meaning, the purchaser of the share is investing €13.98 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.67%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.6%, now sitting on 33.86B for the twelve trailing months.
More news about CRH PLC ord.
6. DASSAULT AVIATION (AM.PA)
30.74% Payout Ratio
Dassault Aviation Société anonyme designs and builds military aircraft, business jets, and space systems in France, the Americas, and internationally. It offers Rafale, a multirole fighter aircraft; nEUROn, an unmanned combat air vehicle; and Falcon aircraft for maritime surveillance, intelligence, and medical evacuation missions. The company operates a fleet of 2,100 Falcon jets and 1,000 military aircraft. In addition, it provides aviation maintenance and training services; repairs and maintains landing gears and flight controls; overhauls and repairs civil aviation equipment; leases and manages Falcon aircraft as part of public passenger transport activity; and designs, produces, and distributes simulation tools. The company was founded in 1916 and is headquartered in Paris, France. Dassault Aviation Société anonyme operates as a subsidiary of Groupe Industriel Marcel Dassault S.A.
Earnings Per Share
As for profitability, DASSAULT AVIATION has a trailing twelve months EPS of €9.76.
PE Ratio
DASSAULT AVIATION has a trailing twelve months price to earnings ratio of 18.79. Meaning, the purchaser of the share is investing €18.79 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.03%.
Volume
Today’s last reported volume for DASSAULT AVIATION is 6670 which is 83.14% below its average volume of 39563.
More news about DASSAULT AVIATION.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Volatility
1’s last week, last month’s, and last quarter’s current intraday variation average was 1.00%, 1.00%, and 1.00%.
1’s highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).
More news about 1.
